Scroll Top


Fondazione Tettamanti with Pavia e Ansaldo in the transfer of license rights to formula pharmaceuticals for the development of a prioritary next-generation immunotheaphy platform in hematologic oncology

Milan, 12 May 2015 – Pavia e Ansaldo assisted Fondazione M. Tettamanti, affiliated to Milan-Bicocca University and  dedicated to research and care of children leukemia and hemopathy, in the exclusive licensing rights to develop its proprietary, next – generation, immunotheraphy platform in hematologic oncology to Formula Pharmaceuticals Inc, a privately-held US oncologic drug development company.

Fondazione Tettamanti was represented by partner Agostino Migone de Amicis and by associates Maria Chiara Biffi and Iolanda Severino.

The exclusive license coincides with the completion of a private investment transaction by the issue of a mandatory convertible bond, facilitated by  Banca Esperia S.p.A. as placement agent and by  IMS Health Capital as financial advisor of Formula Pharmaceuticals Inc.